LNSR Stock Overview
A commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LENSAR, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.55 |
| 52 Week High | US$8.17 |
| 52 Week Low | US$2.12 |
| Beta | 0.58 |
| 11 Month Change | 40.33% |
| 3 Month Change | 63.07% |
| 1 Year Change | 203.21% |
| 33 Year Change | 6.64% |
| 5 Year Change | n/a |
| Change since IPO | -16.11% |
Recent News & Updates
Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
Oct 24
LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Sep 12Recent updates
Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
Oct 24LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Sep 12LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
Jul 16Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
May 01LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
Feb 22Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Jan 24Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
Dec 20Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Oct 21Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
Sep 13This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
Mar 21Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Mar 18Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Nov 01LENSAR GAAP EPS of -$0.67, revenue of $8M
Aug 08LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Mar 23We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth
Jul 28LENSAR EPS misses by $0.23, beats on revenue
May 05What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition
Feb 25We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate
Jan 03Shareholder Returns
| LNSR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.3% | 0.7% |
| 1Y | 203.2% | 20.5% | 32.2% |
Return vs Industry: LNSR exceeded the US Medical Equipment industry which returned 21% over the past year.
Return vs Market: LNSR exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LNSR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LNSR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 130 | Nick Curtis | www.lensar.com |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room.
LENSAR, Inc. Fundamentals Summary
| LNSR fundamental statistics | |
|---|---|
| Market cap | US$87.46m |
| Earnings (TTM) | -US$16.63m |
| Revenue (TTM) | US$48.87m |
1.8x
P/S Ratio-5.3x
P/E RatioIs LNSR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LNSR income statement (TTM) | |
|---|---|
| Revenue | US$48.87m |
| Cost of Revenue | US$24.98m |
| Gross Profit | US$23.89m |
| Other Expenses | US$40.52m |
| Earnings | -US$16.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 48.89% |
| Net Profit Margin | -34.03% |
| Debt/Equity Ratio | 0% |
How did LNSR perform over the long term?
See historical performance and comparison